Key result
Fixed-dose anticoagulation for St. Jude AVR is linked to ~1.4% annual thromboembolism and similar hemorrhage rates.
Why the study?
The safety and efficacy of fixed dose oral anticoagulation without adjustment based on prothrombin time or cardiac rhythm in patients with the St. Jude Medical aortic valve prosthesis were uncertain.
Does fixed dose anticoagulation with warfarin plus antiplatelet therapy provide adequate safety and efficacy in patients undergoing primary aortic valve replacement with a St. Jude Medical mechanical prosthesis?
Cohort (n=865)
Does fixed dose anticoagulation with warfarin plus antiplatelet therapy provide adequate safety and efficacy in patients undergoing primary aortic valve replacement with a St. Jude Medical mechanical prosthesis?
Fixed dose oral anticoagulation with warfarin plus antiplatelet therapy in patients with a St. Jude mechanical aortic valve does not increase thromboembolism rates but fails to reduce bleeding complications.
Answers are grounded in this paper and cite their sources.
Low event rates with fixed dosing do not justify practice change; leaves open randomized validation versus INR-guided therapy.
Over a 10-year period, between 1986 and 1996, 865 patients underwent primary aortic valve replacement (AVR) with the St. Jude Medical mechanical prosthesis. Patients who had undergone valve replacement with a different type of prosthesis previously were excluded from this study. Patient age ranged from 11 to 79 years. The mean age was 42.9 +/- 14.54. The gender distribution was 396 men (45.8%) and 469 women (54.2%). All patients received 2.5 mg/day Coumadin after extubation. A combination of the antiaggregant therapy (Dypridamole 3X 75 mg/day, Asprine 100 mg/day) was added after removal of the chest tubes. The dosage of Coumadin was maintained constant regardless of the prothrombin time (PT) or cardiac rhythm. There were 101 valve-related complications (4.2% per patient year [ppy]) occurring in the late follow-up period. Of these complications; 38 were anticoagulant-related hemorrhage (1.58% ppy), 3 were paravalvular leak (0.12% ppy), and 36 were thromboembolism (1.4% ppy). There were 24 reoperations (0.99% ppy) and 17 late deaths. The linearized late mortality rate was 0.7% ppy. Long-term survival estimates at 5 and 10 years were 97.14 +/- 0.82% and 94.86 +/- 1.54%, respectively. We conclude from the data that the St. Jude Medical valve may allow the use of a low level of anticoagulation. This study shows that fixed dose oral anticoagulation does not increase the rate of thromboembolism in patients with the St. Jude aortic valve. This protocol does not result in reduction of bleeding complications, however.
No takes yet. Share an insight, caveat, or question.
Katırcıoğlu et al. (1997) conducted a cohort in Primary aortic valve replacement (n=865). Fixed dose anticoagulation and antiaggregant therapy was evaluated on Valve-related complications. Fixed-dose oral anticoagulation after St. Jude aortic valve replacement resulted in a thromboembolism rate of 1.4% per patient-year and a hemorrhage rate of 1.58% per patient-year.
Synapse has enriched 10 related papers. Consider them for comparative context: